Inside 340B Report

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton breaking down the latest in 340B news, including a new hospital lawsuit aiming to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot, HRSA's recent webinar about that program, key regulatory updates on Medicare negotiated drug prices and a finalized hospital outpatient rule with significant implications for 340B hospitals and other stakeholders. Key Topics Covered: Hospitals Continue to Oppose Rebate Pilot Will breaks down a hospital group's new lawsuit urging a Maine federal district court to block HRSA from implementing its 340B rebate pilot ahead of its Jan. 1, 2026 launch. He also provides an update on separate 340B rebate litigation before a Washington, D.C. federal appeals court. Shannon highlights a new letter from a different national hospital group urging HRSA to address key concerns with the pilot. Technical Issues Disrupt HRSA's Rebate Webinar Will explains the technical issues that hampered HRSA's highly anticipated Dec. 4 webinar on its 340B rebate pilot program, preventing many stakeholders from joining. He then shares details of the second half of HRSA's webinar that 340B Report was able to access and notes 340B Report will provide additional coverage of the full webinar once it becomes available. CMS Lists New Negotiated Medicare Prices, Finalizes OPPPS Rule Shannon breaks down the Centers for Medicare and Medicaid Services' (CMS) late-November release of  the "maximum fair price" (MFP) it will pay for 15 high-cost Medicare Part D drugs starting in 2027, and how those negotiated prices are expected to compare to the drugs' 340B ceiling prices. She and Ted also discuss 340B provider advocates' concerns with CMS' finalized 2026 Hospital Outpatient Prospective Payment System (OPPS) rule, which includes a Medicare drugs acquisition cost survey and plan to accelerate outpatient payment cuts to offset previous 340B hospital lump sum repayments. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by PharmaForce. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) approval of the final drugmaker 340B rebate pilot plan; oral arguments in a key federal court case centered on 340B rebates; and Kalderos' official entrance into the 340B contract pharmacy claims clearinghouse space. Key Topics Covered: Final Rebate Pilot Model Plans Approved, Additional Details Unveiled Will provides an in-depth look at HRSA's recent approval of Novartis' 340B rebate plan for Entresto—the final drug eligible for the upcoming  pilot program. He also explains provider concerns about the pilot's rollout—including how manufacturers and their vendor defined the claims data field "340B ID"—and HRSA's response seeking to quell those concerns. Appeals Court Hears Oral Arguments in Rebate Case Will discusses oral arguments he attended at a Washington, D.C., federal appeals court that could shape the future of 340B rebates, including HRSA's rebate pilot. Attorneys for the drug industry, the federal government and trade group 340B Health debated who—if anyone—has authority to decide whether drugmakers can offer 340B pricing through a rebate. Will notes that all three sides faced tough questioning from the judges, who appeared well-versed in the nuances of the 340B program. 1st Drugmaker Transitions to Kalderos' Truzo Platform Shannon breaks down the significance of drugmaker Alkermes' recent decision to transition its 340B contract pharmacy policy administration from Second Sight Solutions' 340B ESP platform to Kalderos' Truzo clearinghouse—making it the first drug manufacturer to do so. She also discusses the pushback the Alkermes' short timeline for the shift, which will go live Dec. 1, drew from 340B provider advocates. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) recent approval of drugmaker 340B rebate pilot plans—and the reactions they sparked; major court actions affecting Oklahoma and Colorado's 340B contract pharmacy access laws; and what Abigail Spanberger's (D) Virginia gubernatorial win could mean for 340B policy in that state. Key Topics Covered: Rebate Pilot Model Plans Approved, Unveiled Will provides an in-depth look at the manufacturer rebate pilot plans that HRSA approved, as well as provider frustrations over the pilot's rollout. Shannon breaks down the contrasting reactions to HRSA's plan approvals. 340B providers panned the move and the drug industry embraced it, urging that the model be expanded. She also teases a Dec. 15 340B Report subscriber-only webinar that will focus on the rebate pilot model's implementation.  Federal Courts Block Oklahoma's Contract Pharmacy Law, Back Colorado's Will discusses a pair of conflicting federal district court rulings on 340B contract pharmacy access laws in two states. One judge blocked Oklahoma from enforcing its law while the drug industry litigation plays out, while a different judge denied AbbVie's bid to block enforcement of Colorado's statute. Despite the Oklahoma federal court's ruling, Shannon notes that some drugmakers are exempting covered entities in that state from their contract pharmacy restrictions. Virginia's Gubernatorial Election Implications Shannon breaks down how Spanberger's recent gubernatorial win could bolster advocates' efforts to enact 340B contract pharmacy protections in Virginia. She and Ted discuss Spanberger's leadership on 340B issues in Congress and how the Democrat made prescription drug pricing a key tenet of her 2025 campaign for governor. They also compare Spanberger's actions on 340B to outgoing Gov. Glenn Youngkin (R), who vetoed a widely supported, bipartisan 340B contract pharmacy access bill in 2024 after pressure from a dark-money group. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Senate Health, Education, Labor and Pensions (HELP) Committee's recent hearing on 340B, key takeaways from the 340B Grantees Fall Conference in Atlanta and 340B Report's recent webinar on the Health Resources and Services Administration's (HRSA) 340B rebate pilot and where we may be headed next on that controversial proposal. Key Topics Covered: Senate HELP Committee Mixes 340B Criticisms and Support Shannon and Will provide an in-depth look at the Senate HELP Committee's Oct. 23 hearing on the 340B program, which occurred despite an ongoing federal government shutdown. Shannon discusses the dark money anti-340B campaign now underway in Washington, D.C., and how many provider advocates were pleasantly surprised about how the hearing went. Will explains that while HELP Committee Chair Bill Cassidy (R-La.) reiterated familiar 340B criticisms, many lawmakers from both parties defended the program's importance to providers. He also notes that the hearing often veered off topic, with many Democrats criticizing the government shutdown and health care cuts. Ted also discusses the growing momentum for a bipartisan group of senators' draft bill, the SUSTAIN 340B Act.  He notes that multiple lawmakers expressed support for that effort, including longtime 340B critic Cassidy. Ted also shares insights into the status of the SUSTAIN Act and what might be included in the legislation. Takeaways from 340B Grantees Conference in Atlanta and Industry Conference in NYC Ted and Will discuss their recent trip to Atlanta for the 340B Grantees Fall Conference, where they each moderated panels. Will discusses his panel on state 340B legislative activity and shares providers' concerns that drugmakers could use the 340B program as a bargaining chip in negotiations with the Trump administration on things like direct-to-consumer drug pricing and pharmaceutical tariffs. Ted discusses continued provider concerns with the HRSA's 340B rebate pilot proposal and shares insights on potential 340B negotiations with the Trump administration, which he heard at a separate conference in New York City that had a strong drug industry presence. 340B Report's Rebate Pilot Webinar and Rumblings  Shannon highlights 340B Report's recent subscriber-only webinar on HRSA's 340B rebate pilot proposal, which focused on key implementation concerns and included a lively debate on the rebate proposal's merits. Ted also shares what he is hearing about the status of the rebate model. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs, and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the ongoing federal government shutdown's impact on 340B operations, the latest in the 340B rebate debate and a large drugmaker's move to tighten 340B restrictions on certain hospitals that it believes are not complying with the company's current contract pharmacy policy. Key Topics Covered: Federal Government Shutdown Could Affect 340B Program Operations Shannon explains how the federal government shutdown has led to furloughs at the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs—and what that could mean for stakeholders if the shutdown drags on. She also discusses how the shutdown could impact a key upcoming deadline in HRSA's 340B rebate pilot program. Meanwhile, Ted shares his thoughts on politically-charged language about the shutdown that appeared on HRSA's website and the shutdown's real world effects on the HRSA staff and other federal workers. 340B Rebate Pilot Concerns and Upcoming Exclusive 340B Report Webinar Will discusses 340B stakeholders' continued implementation concerns with HRSA's controversial 340B rebate pilot program, including potentially significant financial and administrative burdens for providers. Will and Ted also preview 340B Report's exclusive, subscriber-only webinar on the biggest implementation questions for 340B stakeholders, which will take place on Oct. 15 and include a panel of experts from across the 340B supply chain. Pfizer Tightens 340B Restrictions, Makes Headlines with 'MFN' Move Shannon discusses Pfizer's recent move informing certain 340B hospitals that they could lose their approved one contract pharmacy exemption registered with industry vendor 340B ESP as of Nov. 1. She also explains Pfizer's headline-grabbing move to offer its drugs to Medicaid at a "most favored nation" price and launch a direct-to-consumer prescription drug platform. Shannon discusses why industry observers don't think it will have as significant an impact as it has been heralded by the White House and Pfizer executives. And why some stakeholders view those moves as undermining the drug industry's arguments that 340B drives higher drug prices. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Verity Solutions. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including one drugmaker's removal of medications from the 340B and Medicaid Drug Rebate programs, recent developments in key 340B drug industry lawsuits and dark money groups' efforts to block Michigan's 340B contract pharmacy and reporting bill. Key Topics Covered: Bausch Health Pulls Drugs From 340B, Medicaid Rebate Programs Shannon discusses Bausch Health's recent decision to remove drugs from the 340B and Medicaid rebate programs effective Oct. 1. She notes that while the terminations will affect hundreds of products associated with many of Bausch Health's national drug codes for 340B-eligible drugs, it's unclear whether Bausch will fully remove itself from the 340B program. Attorneys, however, have suggested that drugmakers can't "pick and choose." Ted discusses providers' responses to the forthcoming terminations, including their concerns about the move's financial implications, patient access to medications and whether other drugmakers will follow suit.  Two More Federal Courts Side With States on Contract Pharmacy Protections Will explains the implications of two recent major federal court rulings in favor of state 340B contract pharmacy access laws. The U.S. 5th Circuit Court of Appeals denied AbbVie's bid to block enforcement of Mississippi's law, reaffirming a lower court's decision. Shortly thereafter, a federal district court in Maine denied AbbVie and Novartis' efforts to halt Maine's law, allowing the statute to take effect as scheduled. Michigan's Contract Pharmacy and Reporting Bill Comes Under Fire  Will also discusses a recent Michigan House hearing over a contract pharmacy access bill with reporting requirements for hospitals and manufacturers. Providers strongly supported the bill, while the drug industry and two dark money groups heavily opposed it. The hearing came amid an ongoing feud between the Michigan House speaker and the leader of the state's hospital association. It also came six months after the state Senate easily passed a similar measure. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Plenful. Plenful is the leading AI workflow automation platform transforming how healthcare teams work. Built to empower operators and the patients they serve, Plenful enables healthcare organizations to scale operations with speed, precision, and intelligence. We are very grateful to Plenful for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the 1,000-plus public comments on the Health Resources and Services Administration's (HRSA) 340B rebate pilot proposal, the 340B ACCESS Act's reintroduction in Congress and a new Congressional Budget Office (CBO) report on 340B program growth, which has drawn criticism from provider advocates. Shannon and Will also provide updates on oral arguments in key federal cases that recently went before appeals court judges.   Key Topics Covered: More than 1,000 Stakeholders Weigh-in on HRSA's 340B Rebate Pilot Proposal Will discusses the more than 1,200 stakeholder comments HRSA received over its contentious 340B rebate pilot proposal. He explains why hundreds of 340B providers urged the agency to abandon the rebate pilot altogether and discusses the drug industry's push to expand the pilot to more drugs. Will also breaks down stakeholders' concerns with the one-week turnaround between the comment due date and manufacturers' deadline to submit rebate proposals. CBO Report and ACCESS Act Reintroduction Take Center Stage on Capitol Hill Shannon breaks down the latest version of the 340B ACCESS Act, a controversial 340B overhaul bill which two key House GOP lawmakers reintroduced on Sept. 10. She discusses how the National Association of Community Health Centers has backed off from supporting the measure, which contains many of the provisions included in the May 2024 original version that providers advocates have vocally opposed. Shannon notes that the bill's reintroduction came one day after the nonpartisan CBO released a report on 340B program growth. Ted highlights provider advocates' criticisms of the report and why they believe it misses the mark. Appeals Courts Hear Arguments in Key 340B-Related Cases Will breaks down a trio of oral arguments that recently took place in federal appeals courts over drug industry challenges to state 340B contract pharmacy access laws. The hearings centered on whether the 340B statute's silence on drug delivery allows states to pass contract pharmacy access measures, and the judges asked tough questions of all parties. Shannon provides an update on recent oral arguments in a 5th Circuit Court of Appeals case surrounding a Centers for Medicare and Medicaid Services rule which could affect some hospitals' 340B program eligibility. A group of Texas hospitals have challenged the rule. A Texas federal District Court in 2024 declared it "unlawful" and halted its enforcement. HHS appealed the decision. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial. Listen to our newest podcast 340B Leaders Upfront We encourage you to check out 340B Report's new business area podcast, 340B Leaders Upfront, formerly 340B 360°, hosted by Anna Mangum. In the latest episode, Anna interviews two of the leaders of Plenful, an AI service provider company that is providing very cost-effective and highly beneficial services for the 340B provider community.

In this episode, Ted Slafsky, publisher and CEO of 340B Report, and Will Newton, associate editor and senior writer at 340B Report, break down the latest in 340B news, including concerns over the Health Resources and Services Administration's (HRSA) controversial 340B rebate pilot program and a new hospital Medicare reclassification trend that is alarming some rural health advocates. Next, they're joined by Colleen Meiman, a senior policy advisor to state primary care associations, to discuss the incredible life and legacy of Sue Veer, a nationally recognized 340B advocate and educator who passed away last week. Key Topics Covered: HRSA Posts Rebate FAQ, Federal Court Extends Rebate Appeal Deadlines Will discusses HRSA's recently published FAQ that clarifies parts of its contentious 340B rebate pilot program. Then, he explains why a major hospital trade group is urging the agency to abandon the rebate pilot altogether. Will also shares recent updates in the drug industry's litigation challenging HRSA's authority to pre-approve rebates. Rural Health Advocates Alarmed by Hospital Reclassification Trend Will discusses an emerging trend in which some large urban hospitals are reclassifying as rural under the Medicare program. This gives them access to benefits designed for rural providers, including higher Medicare payments and a lower 340B eligibility threshold. Will explains why some rural health advocates are concerned this could deplete rural resources and bring negative scrutiny to the 340B program. Ted also discusses the myriad financial challenges hospitals are facing, including recently enacted steep Medicaid cuts that could threaten 340B eligibility for many.  A Tribute to the Life and Legacy of 340B Champion Sue Veer Special guest Colleen Meiman joins the team to mourn the loss of the late Sue Veer and honor her incredible legacy as a nationally respected 340B program advocate and educator. Colleen shares the incredibly powerful story of why Sue began her career in health care, as well as her close personal relationship with Sue. Next, Ted and Colleen discuss Sue's omnipresence in the 340B space, including her various roles with national provider organizations and reputation as a "straight shooter" respected by all sides of the 340B debate., Colleen also shares a few fun stories about Sue unbeknownst to many. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. Visit RxParadigm to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial. Listen to our newest podcast 340B Leaders Upfront We encourage you to check out 340B Report's new business area podcast, 340B Leaders Upfront, formerly 340B 360°, hosted by Anna Mangum. In the latest episode, Anna interviews two of the leaders of Plenful, an AI service provider company that is providing very cost-effective and highly beneficial services for the 340B provider community.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including updates to the comment deadline on the Health Resources and Services Administration's (HRSA) 340B rebate guidance—and why 340B stakeholders say the agency's timeline is not long enough. They also reflect on the implications of a major ruling in an antitrust lawsuit that two health centers filed against drug manufacturers, which were among the first companies to impose 340B contract pharmacy restrictions. The team also discusses new 340B enrollment requirements for sexually transmitted disease (STD) clinics. And Will breaks down a new 340B Report analysis that raises questions about the controversial alliance between the National Association of Community Health Centers (NACHC) and Pharmaceutical Research and Manufacturers of America (PhRMA). Key Topics Covered: HRSA Extends Rebate Pilot Comment Period and HHS Touts Model Shannon offers a recap on HRSA's proposed 340B rebate pilot program, including which drugs would qualify and when manufacturers can deny claims. She discusses a legal filing in which the Health and Human Services (HHS) Department touts its rebate model pilot plan, and she highlights HRSA's recent deadline extension for public comments on the proposal. Ted notes 340B providers' concerns with the rebate model, and why they're asking the agency to extend its consideration timeline for such proposals. Antitrust Case Ruling Sets Stage for Future Litigation Shannon highlights a recent federal appeals court ruling that 340B provider attorneys argue could open the door for future 340B-related lawsuits against drug manufacturers. The U.S. 2nd Circuit Court of Appeals overturned a lower court decision, unanimously ruling that an antitrust class action lawsuit can continue in a lower court. Two community health centers allege in the lawsuit that four major drugmakers illegally colluded to deny 340B pricing on insulin and other diabetes medicines through contract pharmacy restrictions. Ted discusses the legal background surrounding the case and its potential importance. STD Clinic Lawsuits and New Eligibility Requirements Will breaks down multiple lawsuits related to the 340B eligibility of a Nevada-based STD clinic, including multiple sites that HRSA terminated and later reinstated. Shannon notes that a new HRSA proposal would require STD clinics and other 340B covered entities to submit new or more complete information to enroll in or be re-certified in the 340B program. The proposal came just weeks after Office of Pharmacy Affairs (OPA) Director Chantelle Britton hinted at changes affecting STD clinics. Analysis Raises Questions about ASAP 340B Alliance Will discusses his recent analysis of the 340B reform alliance, called ASAP 340B, between the NACHC and PhRMA. Since the two groups formed their unlikely alliance in March 2023, the number of PhRMA member companies that have placed 340B restrictions on health centers has more than doubled—raising questions over how much the alliance has actually benefited NACHC members. Will also breaks down how NACHC's public posture on the alliance has appeared to shift, even as ASAP 340B continues its advocacy efforts and NACHC continues to be listed as one of its founding members. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne, the only independent provider of integrated pharmacy solutions. VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. Visit VytlOne to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) highly anticipated release of proposed 340B rebate guidance—and the significant concerns it garnered from 340B stakeholders. They also reflect on the 340B Coalition's recent summer conference and Capitol Hill lobbying efforts. Key Topics Covered: HRSA Releases 340B Rebate Model Guidance Will discusses the details of HRSA's proposed 340B rebate pilot program, including which drugs would qualify and when manufacturers would be able to deny claims. Though HRSA's proposed 340B rebate pilot, which stakeholders will have 30 days to comment on, is narrower in scope than what had been proposed by various drug makers, it still would mark a dramatic shift to a program that has operated using an upfront discount since its inception more than 30 years ago.  Stakeholders Raise Concerns on Proposed 340B Rebate Pilot Proposal Shannon breaks down how key 340B stakeholders initially responded to HRSA's rebate guidance, including concerns raised by both providers and the drug industry. She notes that hospital groups quickly expressed their opposition to efforts to implement a 340B rebate model, arguing it marks a major departure from how the program's been run and could hurt their financial ability to provide services to low-income patients. Health center groups have not yet weighed in with 340B Report. The drug industry, meanwhile, contends that HRSA's proposal doesn't go far enough and is needed to address what they say are continued challenges in addressing duplicate discounts, Shannon adds.  Key Takeaways from the 340B Coalition's Summer Conference Shannon recaps the 340B Coalition's recent summer conference in National Harbor, Md., including keynote speeches from 340B Health leaders and HRSA's Office of Pharmacy Affairs Director Chantelle Britton. Shannon notes that 340B reform and PBM reform efforts are likely to remain hot topics in Washington, D.C., despite the post-reconciliation budget lull on Capitol Hill. Will discusses covering the fourth annual "Defend 340B" march on Capitol Hill, which took place after the conference and was unaffiliated with the 340B Coalition. He also discusses competing lobbying efforts from two trade groups that took place that week. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Pillr Health, a company known for its 340B solutions that emphasize transparency, integrity, and ease of use for covered entities. Visit Pillr Health to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 20: Reconciliation Bill's 340B Impact, CMS' Big 340B Proposals and Rebate Update In this episode, 340B Report Publisher & CEO Ted Slafsky and 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest 340B news, including key developments in Washington D.C., a federal 340B rebate court case and the ongoing lobbying effort of the White House's Office of Management and Budget over a potential rebate model. Ted closes the episode with a touching tribute to his late mentor David Gergen. Key Topics Covered: Reconciliation Bill Becomes Law, Key Congressional Subpanel Updates Leaders  Shannon and Will discuss the recent enactment of the GOP-backed reconciliation bill, known as the "Big Beautiful Bill," including what its massive health spending cuts over the next decade could mean for 340B providers. Shannon highlights how 340B-related provisions stripped from the wide-ranging spending legislation have been reintroduced as part of a large bipartisan standalone bill focused on the Pharmacy Benefit Manager industry. And Ted discusses recent leadership changes on the House Energy and Commerce Health Subcommittee following U.S. Rep. Buddy Carter's (R-Ga.) decision to step down as chair as he runs for U.S. Senate. CMS Proposes Rules With Major 340B Implications Shannon and Will break down how two new Centers for Medicare and Medicaid Services (CMS) proposed rules would affect the 340B program. Shannon offers an overview of CMS' Outpatient Prospective Payment System (OPPS) draft rule and its significant implications for the 340B community. It contains controversial provisions to accelerate hospital outpatient payment cuts to offset previous 340B hospital lump sum repayments, as well as plans to survey hospital acquisition costs for certain outpatient medications. Next, Will discusses CMS' proposal to establish, for the first time, claims-based approaches to identifying 340B claims billed to Medicare Part D. 340B Rebate Model Debates Heats Up Will discusses the latest in drug industry efforts to implement controversial 340B rebate models. Four drugmakers are currently appealing a pair of lower courts' rebate rulings, while dozens of program stakeholders—including drugmakers, providers and technology vendors—are meeting with federal officials in an effort to sway highly anticipated federal 340B rebate guidance. Tribute to David Gergen Ted offers a touching tribute to David Gergen, his first mentor and boss out of college. Gergen was a senior adviser to four U.S. presidents and a highly influential editor and political commentator. Ted reflects on his inspiring career and shares his thoughts on his mentorship. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including key developments in a federal 340B rebate model court case, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.'s latest remarks on the Trump administration's efforts to lower prescription drug prices and two New England states' embrace of new 340B contract pharmacy access and provider reporting laws. Key Topics Covered: Appeals Court Expedites Schedule in 340B Rebate Case  Will recaps recent developments in the drug industry efforts to convert upfront 340B discounts to post-purchase rebate models. After a federal district court in Washington, D.C. ruled that drugmakers cannot implement 340B rebates without HHS approval, multiple drug companies appealed. Meanwhile, hospital trade group 340B Health filed a cross-appeal arguing that the court should have ruled that the 340B statute "categorically prohibits" rebates. While those appeals play out, stakeholders are also meeting with HHS about the agency's 340B rebate guidance, which is not yet public pending regulatory review. RFK Jr. Touts Administration's Drug Pricing Plans, Key Lawmaker Talks 340B Shannon breaks down Kennedy's recent appearance before the House Energy and Commerce Committee's Health Subcommittee to testify on President Donald Trump's budget proposal. While the HHS secretary did touch on the budget's controversial plan to shift 340B oversight within the agency, Shannon notes that he touted the administration's efforts to lower prescription drug prices through recent executive actions and endorsed pharmacy benefit manager reform efforts. She discusses how U.S. Rep. Diana Harshbarger (R-Tenn.) briefly floated the potential for renegotiated "340B contracts" during her exchange with Kennedy—comments which some 340B advocates criticized as a misunderstanding of the 340B program's structure. Will provides an update on another drug pricing executive order. New England States Embrace Contract Pharmacy Access, Provider Reporting Laws  Will provides an update on Maine's recent enactment of a contract pharmacy access and reporting law. Shannon notes that Rhode Island is on the cusp of signing similar legislation into law. With 20 states now having enacted contract pharmacy protections, Will breaks down the latest trends in state 340B legislation. He discusses the increasing number of states that have passed bills that contain both contract pharmacy access and reporting provisions in 2025.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. CompassRx sponsored this week's episode. CompassRx is the premier AI-services platform built exclusively for 340B covered entities. We are very grateful to CompassRx for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 18: Impending Rebate Guidance, Possible 340B Move from HRSA to CMS & Oklahoma's Veto Override In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the U.S. Department of Health and Human Services' (HHS) submission of 340B rebate guidance for regulatory review, a proposal to shift 340B oversight to the Centers for Medicare & Medicaid Services (CMS), U.S. Sen. Bill Cassidy's (R-La.) latest comments on 340B and Oklahoma's 340B contract pharmacy legislation veto override. In This Episode:  Rebate Updates  Will provides an update on the latest surrounding drugmakers' attempts to convert upfront 340B discounts to a post-purchase rebate model. He discusses HHS' June 1 submission of proposed 340B rebate guidance to the Office of Management and Budget, which will remain confidential throughout the review. Meanwhile, drugmakers Novartis and Bristol Myers Squibb filed an emergency motion to expedite their legal challenge to a ruling that affirms the government's authority to pre-approve 340B rebate models—citing looming compliance deadlines under the Inflation Reduction Act. A Proposed Shift to CMS and Other Federal Happenings  Shannon and Ted break down President Donald Trump's full HHS budget request that calls for moving the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs (OPA), which oversees the 340B program, to CMS. They discuss the differences between the formal proposal and a version included in a leaked document, as well as 340B stakeholders' reaction to such a move. Shannon and Ted also discuss key federal players on 340B, including Cassidy's latest remarks on potential congressional reform plans and the return to the private sector of Katie Miller, a Trump adviser tied to a dark-money group running anti-340B ads in various states. The State of the States  Will recaps Oklahoma's path to enacting a contract pharmacy access law, which included a gubernatorial veto and legislative override. He and Bella discuss the latest state-level action on 340B bills, as well as how drugmakers have responded to Tennessee's unique contract pharmacy access law. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce sponsored this week's episode. PharmaForce is the only Third Party Administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.  

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including a major federal court ruling on drugmaker 340B rebate models, Health and Human Services (HHS) Secretary Robert F Kennedy Jr.'s first public comments on the 340B program and the Oklahoma governor's decision to veto a widely supported contract pharmacy access bill. Key Topics Covered: Court Upholds HHS' Right to Pre-Approve 340B Rebates Will recaps the latest developments in a key 340B rebate lawsuit, including a recent opinion from the Washington D.C. U.S. District Court that rejected drugmakers' claims that HHS acted unlawfully by requiring pre-approval of their 340B rebate proposals. He dives into the implications of the ruling, which doesn't rule out the possibility of drugmaker rebates in the future, what it means for stakeholders and how key 340B players responded.  RFK Jr. Offers 1st Public Comments on 340B, Trump Issues Drug Pricing EO  Shannon breaks down Kennedy's first public comments on the 340B program, which came during his recent testimony before House and Senate subcommittees. She and Ted discuss how the HHS secretary's comments about the program largely reflect drug industry talking points, as well as the pushback the comments drew from 340B providers. Shannon also offers an update on budget reconciliation talks and discusses President Donald Trump's new "most-favored nation" drug pricing executive order. She and Ted note the challenges the White House could face in advancing efforts to lower drug prices. Oklahoma Governor Vetoes Contract Pharmacy Bill Following Dark-Money Campaign Will provides an update on Oklahoma's efforts to pass contract pharmacy access legislation after Gov. Kevin (R) vetoed a bill, which cleared the legislature with widespread support. Will discusses the role that misleading dark-money ads may have played in the governor's decision, and how GOP lawmakers, who were the lead sponsors of the 340B legislation, are pushing to override that veto. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. RxParadigm sponsored this week's episode. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editor and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including developments in two major 340B lawsuits, new state contract pharmacy access laws with unique twists and developments on health funding negotiations and drug pricing policy talks in Washington, D.C. Key Topics Covered: Courts Hear Arguments in 340B Rebate, Antitrust Lawsuits Will recaps the latest developments in a key 340B rebate lawsuit, including recent oral arguments in which the drug industry argued it doesn't need federal approval to institute rebate models. HHS has told the drug manufacturers that they are not allowed to unilaterally implement a rebate model and a hospital group has intervened to oppose the use of rebates.  The judge grilled attorneys representing both the drug industry and the Department of Health and Human Services (HHS). HHS later committed to issuing guidance on a rebate model—and what conditions, if any, they could be permitted—within the next few weeks. Bella recaps the recent oral arguments in a 340B antitrust case against four major insulin manufacturers. Ted and Bella discuss the significant implications of this case for 340B covered entities, should the appeals court side with the two health centers that have accused drugmakers of colluding on contract pharmacy restrictions. More States Advance Contract Pharmacy Bills Will provides an overview of recent contract pharmacy access bill developments in Oklahoma, Colorado and Hawaii. He notes some of the unique provisions contained in those bills, such as new reporting requirements for providers.   Drug Pricing Talks Loom Large Shannon breaks down the latest developments on Capitol Hill as congressional Republicans work to wrap up wide-ranging spending legislation, which calls for $880 billion in health spending cuts that are largely expected to target Medicaid. The White House has proposed tying Medicaid drug prices to the prices paid in other affluent countries—a policy which has drawn pushback from both the drug industry and provider advocates. Ted recalls a similar initiative President Donald Trump pursued in his first term to tie dozens of Medicare Part B drugs prices to their international equivalents. Shannon also discusses new federal drug pricing legislation and Trump's HHS budget blueprint.   Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   Each episode is brought to you by one of our great Ultra Diamond sponsors. Maxor sponsored this week's episode. From specialty pharmacies to comprehensive pharmacy management, Maxor optimizes the pharmacy experience for patients and partners. We are very grateful to Maxor for its sponsorship.   Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher & CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski to break down the latest developments in the 340B space. The team discusses Senate HELP Committee Chair Bill Cassidy's (R-La.) high-profile report on the 340B program, an executive order sparking concerns among providers, reactions to potential pharmaceutical tariffs and important state 340B bills in Indiana and Tennessee. Key Topics Covered: Senate Report Calls for Congressional 340B Reform Sen. Cassidy unveiled the long-awaited findings of his two-year investigation into the 340B program with a 200-page report that criticized multiple 340B providers and called for significant congressional 340B reform that echoes many drug industry policy asks. Shannon and Ted discuss the implications of the report and stakeholder reactions to it, as well as the latest on a separate bipartisan Senate 340B legislative effort that's expected to be more provider friendly.  Executive Order and Tariffs Spark Concerns Will Newton breaks down President Donald Trump's (R) recent executive order that attempts to revive a controversial rule requiring health centers to pass all 340B savings on insulin and EpiPens directly to certain low-income patients. The order also calls for a survey on hospital acquisition costs—the likely precursor to an attempt to reduce Medicare Part B payments to 340B hospitals. Providers have raised alarm bells over both proposals. Bella discusses the administration's proposed tariffs on pharmaceuticals and why both drugmakers and provider advocates are warning that they could be problematic for the pharmaceutical supply and patients. State 340B Bills in Indiana and Tennessee Will breaks down a 340B hospital reporting bill in Indiana and a contract pharmacy bill in Tennessee that are both likely to soon become law. Tennessee's unique bill grandfathers in existing drugmaker 340B restrictions but requires the "winners-only" contract pharmacy model that's popular among providers.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This week's episode is sponsored by Pillr Health, a company known for its 340B solutions that emphasize transparency, integrity, and ease of use for covered entities. Visit PillrHealth.com to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.  

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the latest states to enact contract pharmacy access laws, updates in key lawsuits and new U.S. Department of Health and Human Services (HHS) restructuring efforts. Key Topics Covered: New State Contract Pharmacy Access Laws Will highlights new contract pharmacy access laws enacted in Nebraska and Utah, including when they take effect and how their respective state governors approached the legislation. He also briefly discusses New Mexico's newly enacted contract pharmacy access law, which does not take effect until 2026 and is the only enacted state contract pharmacy protection statute that only applies to health centers. Key Updates in Drug Industry Lawsuits and State Enforcement Action Will also breaks down a Minnesota federal district judge's order to dismiss two drug industry lawsuits challenging that state's contract pharmacy access law. The judge ruled that the drugmakers had no legal standing to sue the state over its contract pharmacy law since Minnesota's law—unlike most other existing state contract pharmacy protection statutes—has no enforcement mechanism. Meanwhile, in Arkansas, a state official recently ordered AstraZeneca to restore access to 340B drugs at all contract pharmacy locations. AstraZeneca had been the only major manufacturer not to comply with Arkansas' first-in-the-nation contract pharmacy access law after a federal appeals court panel unanimously upheld the statute in March 2024. A New CMS Leader and HHS Restructuring Shannon and Bella provide an update on 340B-related activity at the federal level. Bella discusses the U.S. Senate's recent confirmation of Mehmet Oz as the new administrator of the Centers for Medicare and Medicaid Services (CMS). Shannon highlights the recent restructuring at HHS and rumored efforts to move the 340B program into CMS.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, the Inside 340B Report team dives into a flurry of activity at the state and federal levels. Publisher and CEO Ted Slafsky and Associate Editor/Senior Writers Shannon Young and Will Newton break down the unprecedented wave of state-level 340B contract pharmacy access and provider reporting bills, explore key federal movements, including the latest on the bipartisan U.S. Senate working group behind the SUSTAIN 340B Act, and provide an update on 340B rebate litigation. Key Topics Covered: State Legislative Activity Heats Up The team discusses the recent surge in legislative action on state 340B bills as more than 25 states have introduced contract pharmacy access bills in 2025. South Dakota and Utah recently enacted contract pharmacy laws in 2025, joining eight other states that passed similar bills in previous years, while bills in New Mexico and North Dakota are awaiting action from their state governors. Will also highlights several state bills that would place a range of reporting requirements—and in some cases significant restrictions—on 340B providers. Federal Legislative Developments and Bipartisan Efforts Shannon provides updates on the latest developments on the 340B front in Washington, D.C., including the new members of the bipartisan group of six senators working on 340B overhaul legislation known as the SUSTAIN 340B Act. She and Ted also highlight other federal bills that could resurface this session, including the provider-supported 340B PATIENTS Act and drug industry-backed 340B ACCESS Act. The team also provides an update on Mehmet Oz's nomination to lead the Centers for Medicare & Medicaid Services (CMS), focusing on a new Washington Post story that highlighted 340B Report's previous reporting on his undisclosed ties to ZorroRx, a health benefits company that partners with 340B hospitals. Despite facing new ethics concerns, Oz has not drawn much scrutiny from lawmakers during the confirmation process over his 340B ties or stance on the program—a shift from previous nominees. Rebate Litigation Developments Will explains recent developments in ongoing lawsuits that pharmaceutical giants, like Johnson & Johnson and Eli Lilly, have filed against the federal Health Resources and Services Administration (HRSA) in their attempts to unilaterally impose 340B rebate models. Notably, in a series of recent court filings, President Donald Trump's (R) administration has chosen to continue to defend HRSA's long-standing position that drugmakers cannot implement 340B rebate models without explicit agency approval, offering some relief to the 340B provider community. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize your 340B savings and operational efficiency. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode of Inside 340B Report, Ted Slafsky, Will Newton and Bella Czajkowski explore the latest developments in the 340B world at both the state and federal levels. They cover the progress of contract pharmacy access bills across the country—including a breaking news development—plus dark money efforts to oppose the legislation. They also break down key updates in drugmaker rebate lawsuits and provide an update on federal budget talks including major cuts expected for the Medicaid program and where we may be headed on the 340B program. Key Topics Covered: Contract Pharmacy Bills Progress, Despite Resistance                                                                           Will summarizes recent key votes on state contract pharmacy access bills and provider reporting legislation. He also breaks the news that South Dakota became the first state in 2025 to enact contract pharmacy protections after hearing from the governor's office mid-recording. Meanwhile, Bella highlights the tactics of dark money efforts to oppose contract pharmacy legislation through misleading ads, noting that many of the efforts appear to be backfiring. Drugmaker Rebate Litigation Heats Up                                                                                                        The team discusses five drugmakers' ongoing legal efforts to implement 340B rebate models without approval from the Health Resources and Services Administration. Bella and Will explain the significance of the recent decision allowing the hospital advocacy group 340B Health and two of its member hospitals to intervene in four of those cases, all while other major provider advocacy groups have filed amicus briefs opposing the rebate models. Budget Talks and the Looming Federal Shutdown                                                                                     With crucial budget negotiations unfolding in Congress, Ted breaks down the potential impact of proposed healthcare funding cuts totaling $880 billion over the next decade. These cuts could have significant effects on Medicaid, directly affecting 340B providers and the patients they serve. Ted notes that 340B stakeholders should keep a close eye on Capitol Hill as budget battles continue, especially given the possibility of a government shutdown.  He also talks about the leaders of key committees with jurisdiction over the 340B program and what that could mean for 340B stakeholders. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We're grateful to PharmaForce for making this episode possible. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode of Inside 340B Report, Ted Slafsky, Shannon Young, Will Newton and Bella Czajkowski discuss what may be a record-breaking year for state contract pharmacy access legislation with more than 20 states having already introduced such bills in 2025. On the federal front, the U.S. House's budget blueprint targeting $880 billion in health spending cuts over the next decade has raised alarm bells among providers over potential significant Medicaid reductions. Finally, Ted and Shannon share takeaways from last week's 340B Coalition Winter Conference in San Diego, where these topics and others were center stage. Key Topics Covered: State Legislative Surge and Legal Developments As of Feb. 28, at least 21 states had introduced new contract pharmacy access bills. Ted and Bella discuss the significance of major states like California, Texas and New York joining the fray with their own 340B access bill proposals. Will also discusses several of the states that have advanced their contract pharmacy bills, before joining Ted and Bella to provide updates on critical legal battles unfolding in states that have already passed contract pharmacy access laws, including Missouri, Kansas and West Virginia.  Budget Blueprint and Medicaid Concerns In Washington, D.C., the House recently passed a budget framework that calls for $880 billion in health spending cuts over the next decade. Shannon discusses the potential implications for Medicaid funding and how these budgetary moves might indirectly impact the 340B program.  340B Coalition Conference Insights Shannon and Ted break down the key issues that dominated the 340B Coalition's recent Winter Conference, including the status of three key federal 340B bills, new scrutiny U.S. Sen. Bill Cassidy (R-La.) could bring to the 340B program as the new HELP Committee chairman and how a Washington D.C. dark-money group's campaign targeting 340B access bills could play out at statehouses. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Pillr Health sponsored this week's episode. Pillr Health is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations. It focuses on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program and beyond. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.